Edition:
United States

Nuvo Pharmaceuticals Inc (NRI.TO)

NRI.TO on Toronto Stock Exchange

5.26CAD
10:47am EDT
Change (% chg)

$-0.09 (-1.68%)
Prev Close
$5.35
Open
$5.30
Day's High
$5.30
Day's Low
$5.26
Volume
3,021
Avg. Vol
19,792
52-wk High
$8.35
52-wk Low
$5.00

Latest Key Developments (Source: Significant Developments)

Nuvo Pharmaceuticals net income from cont ops $1.7 mln
Wednesday, 1 Mar 2017 05:00pm EST 

Nuvo Pharmaceuticals Inc : Nuvo Pharmaceuticals announces 2016 year-end and fourth quarter results . Q4 revenue C$5.6 million versus C$7.7 million . Nuvo Pharmaceuticals - total revenue for three months ended Dec 31, 2016 was $5.6 million compared to $7.7 million for three months ended December 31, 2015 . Nuvo Pharmaceuticals - net income from continuing operations $1.7 million for three months ended Dec 31, 2016 compared to $4.7 million for three months ended Dec 31, 2015 .Nuvo Pharmaceuticals Inc- company expects pennsaid 2% phase 3 trial to be completed and top-line results available in Q2 2017.  Full Article

Nuvo Pharmaceuticals reports Q3 revenue of C$5.5 million
Thursday, 10 Nov 2016 05:30pm EST 

Nuvo Pharmaceuticals Inc : Nuvo Pharmaceuticals Inc - net income from continuing operations for Q3 of 2016 was $1.3 million compared to $2.1 million . Nuvo anticipates signing licensing agreements of pennsaid 2pct covering multiple countries beginning in 2017 . Nuvo Pharmaceuticals™ announces 2016 third quarter results .Q3 revenue C$5.5 million.  Full Article

Nuvo Pharmaceuticals appoints Mary-Jane Burkett as new CFO
Thursday, 1 Sep 2016 04:30pm EDT 

Nuvo Pharmaceuticals Inc :Says Mary-Jane Burkett, has been appointed by its board of directors as vice president and chief financial officer of co.  Full Article

Nuvo Pharmaceuticals posts Q2 earnings per share C$0.22
Wednesday, 10 Aug 2016 05:00pm EDT 

Nuvo Pharmaceuticals Inc : Nuvo Pharmaceuticals announces 2016 second quarter results . Q2 revenue C$8.1 million versus C$3.0 million . Q2 earnings per share C$0.22 from continuing operations .Q2 earnings per share C$0.22.  Full Article

Nuvo Pharma Q2 basic earnings from cont ops $0.22/shr
Wednesday, 10 Aug 2016 05:00pm EDT 

Nuvo Pharmaceuticals Inc :Basic earnings per share from continuing operations for q2 of 2016 was $0.22.  Full Article

Nuvo Pharmaceuticals- Pennsaid trial to support regulatory approvals in E.U., Canada And Australia
Wednesday, 13 Jul 2016 07:30am EDT 

Nuvo Pharmaceuticals Inc : Topline results of trial are expected to be available in late Q2 or early Q3 2017 . Nuvo Pharmaceuticals™ Inc announces Pennsaid 2% phase 3 trial to support regulatory approvals in the E.U., Canada and Australia .Nuvo Pharmaceuticals Inc says trial will cost approximately cdn$1.5 million spread over second half of 2016 and first half of 2017.  Full Article

Nuvo Pharmaceuticals announces Q1 results
Wednesday, 11 May 2016 06:29pm EDT 

Nuvo Pharmaceuticals Inc : Total revenue for Q1 of 2016 increased to $7.8 million from $7.7 million for Q4 of 2015 .Net income from continuing operations for Q1 of 2016 was $1.9 million compared $4.7 million for Q4 of 2015.  Full Article

Nuvo Research says intends to split into two publicly traded cos
Tuesday, 15 Sep 2015 07:00pm EDT 

Nuvo Research Inc:Says Nuvo shareholders to receive shares of both companies.Says one company would be a biotech company focused on drug development.Says the proposed transaction is subject to certain conditions, including final approval by the Nuvo board of directors.Says if approved by shareholders, co expects the proposed transaction would be completed in early 2016.  Full Article

Nuvo Research Announces U.S. Patent for Topical Foamed Formulations that Include DMSO
Thursday, 20 Aug 2015 07:30am EDT 

Nuvo Research Inc:Announces that the United States Patent Office has granted U.S. patent no. 9,107,823 ('823 Patent) covering novel topical foam formulations that include dimethyl sulfoxide (DMSO) together with certain drug actives.  Full Article

Nuvo research receives health Canada approval to conduct new Wf10 phase 2
Monday, 8 Jun 2015 07:30am EDT 

Nuvo Research:receives health Canada approval to conduct new Wf10(TM) phase 2 trial.Says the 2015 wf10 trial will commence this month.Says topline results from trial will be available in late Q4 2015 or early Q1 2016.If trial is successful, co plans to continue development in independently financed entity that will include participation of Nuvo shareholders.Says should the trial be unsuccessful, the company plans to discontinue wf10 development.  Full Article

More From Around the Web

BRIEF-Nuvo Pharmaceuticals net income from cont ops $1.7 mln

* Nuvo Pharmaceuticals announces 2016 year-end and fourth quarter results